Compare Stocks: TARA, OLMA, LXRX, and RIGL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LXRX Lexicon Pharmaceuticals	$2.05 +0.5%	$2.27	$1.10 ▼ $2.68	$912.16M	1.02	2.25 million shs	7.46 million shs
OLMA Olema Pharmaceuticals	$9.82 -0.8%	$11.00	$6.65 ▼ $36.26	$859.23M	1.98	867,143 shs	3.06 million shs
RIGL Rigel Pharmaceuticals	$46.64 +1.7%	$43.03	$24.95 ▼ $52.24	$862.93M	1.2	229,851 shs	939,562 shs
TARA Protara Therapeutics	$3.55 -4.1%	$3.95	$3.11 ▼ $7.82	$209.79M	1.49	484,519 shs	3.95 million shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LXRX Lexicon Pharmaceuticals	0.00%	+2.50%	-5.96%	+1.99%	+88.07%
OLMA Olema Pharmaceuticals	0.00%	-3.91%	-9.91%	+3.26%	+26.71%
RIGL Rigel Pharmaceuticals	0.00%	-1.27%	+3.07%	+41.72%	+36.29%
TARA Protara Therapeutics	0.00%	-7.07%	-8.97%	-10.80%	+17.16%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LXRX Lexicon Pharmaceuticals	$2.05 +0.5%	$2.27	$1.10 ▼ $2.68	$912.16M	1.02	2.25 million shs	7.46 million shs
OLMA Olema Pharmaceuticals	$9.82 -0.8%	$11.00	$6.65 ▼ $36.26	$859.23M	1.98	867,143 shs	3.06 million shs
RIGL Rigel Pharmaceuticals	$46.64 +1.7%	$43.03	$24.95 ▼ $52.24	$862.93M	1.2	229,851 shs	939,562 shs
TARA Protara Therapeutics	$3.55 -4.1%	$3.95	$3.11 ▼ $7.82	$209.79M	1.49	484,519 shs	3.95 million shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LXRX Lexicon Pharmaceuticals	0.00%	+2.50%	-5.96%	+1.99%	+88.07%
OLMA Olema Pharmaceuticals	0.00%	-3.91%	-9.91%	+3.26%	+26.71%
RIGL Rigel Pharmaceuticals	0.00%	-1.27%	+3.07%	+41.72%	+36.29%
TARA Protara Therapeutics	0.00%	-7.07%	-8.97%	-10.80%	+17.16%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LXRX Lexicon Pharmaceuticals	2.25	Hold	$4.55	121.95% Upside
OLMA Olema Pharmaceuticals	2.77	Moderate Buy	$40.60	313.44% Upside
RIGL Rigel Pharmaceuticals	2.57	Moderate Buy	$59.00	26.50% Upside
TARA Protara Therapeutics	2.75	Moderate Buy	$26.25	639.44% Upside

Current Analyst Ratings Breakdown

Latest TARA, OLMA, LXRX, and RIGL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/14/2026	OLMA Olema Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$48.00 ➝ $30.00
9/9/2026	RIGL Rigel Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)
8/31/2026	OLMA Olema Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/25/2026	RIGL Rigel Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B-) ➝ Hold (C+)
8/17/2026	OLMA Olema Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/17/2026	RIGL Rigel Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$40.00 ➝ $49.00
8/17/2026	RIGL Rigel Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/14/2026	RIGL Rigel Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$57.00 ➝ $85.00
8/13/2026	OLMA Olema Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$52.00 ➝ $46.00
8/11/2026	OLMA Olema Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$38.00 ➝ $36.00
8/11/2026	OLMA Olema Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$59.00

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LXRX Lexicon Pharmaceuticals	$49.80M	18.32	N/A	N/A	$0.30 per share	6.83
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	$5.88 per share	N/A
RIGL Rigel Pharmaceuticals	$294.28M	2.93	$6.74 per share	6.92	$21.57 per share	2.16
TARA Protara Therapeutics	N/A	N/A	N/A	N/A	$3.80 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LXRX Lexicon Pharmaceuticals	-$50.34M	-$0.15	N/A	N/A	N/A	-147.38%	-37.53%	-24.96%	11/5/2026 (Estimated)
OLMA Olema Pharmaceuticals	-$162.45M	-$2.12	N/A	N/A	N/A	N/A	-48.26%	-43.04%	11/9/2026 (Estimated)
RIGL Rigel Pharmaceuticals	$367.02M	$16.32	2.86	10.80	N/A	116.30%	22.95%	17.19%	11/3/2026 (Estimated)
TARA Protara Therapeutics	-$57.44M	-$1.35	N/A	N/A	N/A	N/A	-41.72%	-38.78%	11/9/2026 (Estimated)

Latest TARA, OLMA, LXRX, and RIGL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	TARA Protara Therapeutics	-$0.3257	-$0.36	-$0.0343	-$0.36	N/A	N/A
8/10/2026	Q2 2026	OLMA Olema Pharmaceuticals	-$0.5515	-$0.61	-$0.0585	-$0.61	N/A	N/A
8/6/2026	Q2 2026	LXRX Lexicon Pharmaceuticals	-$0.0502	-$0.06	-$0.0098	-$0.07	$3.99 million	$0.69 million
8/4/2026	Q2 2026	RIGL Rigel Pharmaceuticals	$0.0877	$0.88	+$0.7923	$0.88	$55.28 million	$78.70 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
LXRX Lexicon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RIGL Rigel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TARA Protara Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LXRX Lexicon Pharmaceuticals	0.29	13.37	13.29
OLMA Olema Pharmaceuticals	0.01	8.86	8.86
RIGL Rigel Pharmaceuticals	N/A	1.94	1.79
TARA Protara Therapeutics	N/A	10.97	10.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LXRX Lexicon Pharmaceuticals	74.70%
OLMA Olema Pharmaceuticals	91.78%
RIGL Rigel Pharmaceuticals	66.23%
TARA Protara Therapeutics	38.13%

Insider Ownership

Company	Insider Ownership
LXRX Lexicon Pharmaceuticals	14.00%
OLMA Olema Pharmaceuticals	12.56%
RIGL Rigel Pharmaceuticals	10.47%
TARA Protara Therapeutics	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LXRX Lexicon Pharmaceuticals	81	444.96 million	382.66 million	Optionable
OLMA Olema Pharmaceuticals	150	87.50 million	76.51 million	Optionable
RIGL Rigel Pharmaceuticals	174	18.50 million	16.57 million	Optionable
TARA Protara Therapeutics	51	59.10 million	54.60 million	Optionable

TARA, OLMA, LXRX, and RIGL Headlines

Recent News About These Companies

Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

September 8, 2026 | globenewswire.com

Protara Therapeutics (NASDAQ:TARA) Upgraded to Sell at Wall Street Zen

September 5, 2026 | marketbeat.com

Bank of America Corp DE Buys 430,014 Shares of Protara Therapeutics, Inc. $TARA

August 29, 2026 | marketbeat.com

Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Consensus Rating of "Moderate Buy" from Brokerages

August 29, 2026 | marketbeat.com

Protara’s TARA-002 Moves Into Pivotal Bladder Cancer Trial: What Investors Should Watch

August 21, 2026 | tipranks.com

Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

August 12, 2026 | markets.businessinsider.com

Protara Therapeutics: Orphan Drug Indications Drive A Heavily Undervalued Pipeline

August 11, 2026 | seekingalpha.com

What Makes Protara Therapeutics (TARA) a New Buy Stock

July 21, 2026 | zacks.com

Protara Therapeutics Announces Key Medical Leadership Transition

June 29, 2026 | tipranks.com

Foghorn Therapeutics (FHTX) Receives a Buy from H.C. Wainwright

May 21, 2026 | theglobeandmail.com

Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

May 20, 2026 | globenewswire.com

Protara Therapeutics, Inc. (TARA) Discusses Interim Safety and Durability Data From STARBORN-1 Trial of TARA-002 in Lymphatic Malformations Transcript

May 19, 2026 | seekingalpha.com

Protara’s cell therapy shows treatment durability in mid-stage NMIBC study

May 19, 2026 | msn.com

Protara Therapeutics to Host Virtual Webinar on Lymphatic Malformations and TARA-002 Clinical Program

May 18, 2026 | quiverquant.comQ

Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026

May 18, 2026 | globenewswire.com

Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of ...

May 15, 2026 | markets.businessinsider.com

Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC

May 15, 2026 | globenewswire.com

Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update

May 13, 2026 | globenewswire.com

One Protara Therapeutics Insider Raised Their Stake In The Previous Year

May 4, 2026 | finance.yahoo.com

Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association ...

April 28, 2026 | markets.businessinsider.com

Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting

April 27, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TARA, OLMA, LXRX, and RIGL Company Descriptions

Lexicon Pharmaceuticals NASDAQ:LXRX

$2.05 +0.01 (+0.49%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$2.08 +0.03 (+1.66%)

As of 09/18/2026 07:35 PM Eastern

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Olema Pharmaceuticals NASDAQ:OLMA

$9.82 -0.08 (-0.81%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$9.85 +0.03 (+0.27%)

As of 09/18/2026 07:55 PM Eastern

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Rigel Pharmaceuticals NASDAQ:RIGL

$46.64 +0.79 (+1.72%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$46.25 -0.39 (-0.84%)

As of 09/18/2026 07:47 PM Eastern

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

Protara Therapeutics NASDAQ:TARA

$3.55 -0.15 (-4.05%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$3.55 0.00 (0.00%)

As of 09/18/2026 07:30 PM Eastern

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TARA, OLMA, LXRX, and RIGL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TARA, OLMA, LXRX, and RIGL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TARA, OLMA, LXRX, and RIGL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TARA, OLMA, LXRX, and RIGL Company Descriptions

Lexicon Pharmaceuticals NASDAQ:LXRX

Olema Pharmaceuticals NASDAQ:OLMA

Rigel Pharmaceuticals NASDAQ:RIGL

Protara Therapeutics NASDAQ:TARA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TARA, OLMA, LXRX, and RIGL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TARA, OLMA, LXRX, and RIGL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TARA, OLMA, LXRX, and RIGL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TARA, OLMA, LXRX, and RIGL Company Descriptions

Lexicon Pharmaceuticals NASDAQ:LXRX

Olema Pharmaceuticals NASDAQ:OLMA

Rigel Pharmaceuticals NASDAQ:RIGL

Protara Therapeutics NASDAQ:TARA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools